63 results about "D-glucitol" patented technology

The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate.

A cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline. It is a cocrystal of known compound A, which has a constant quality, is superior in storage stability, has no moisture absorptivity, and is suitable as a crystal of a drug substance used for preparing pharmaceuticals.

The invention discloses a polyurethane composition for glass fiber reinforced honeycomb sandwich panels and an application method of the polyurethane composition. The polyurethane composition comprises a component A and a component B; the component A comprises 40-70% of polyether polyol 1, 5-10% of polyether polyol 2, 5-10% of polyether polyol 3, 0-10% of polyester polyol 1, 4-10% of crosslinkingagents, 5-15% of chain extenders, 0.2-2% of foam stabilizers, 0.2-1.5% of catalysts, 5-10% of flame retardants, 0.2-1% of water, 0.2-2% of internal releasing agents and 0.2-1% of other additive; the component B comprises polyaryl polymethylene isocyanate; the polyether polyol 1 is prepared by taking D-glucitol as an initiator and alkali metal hydroxide as a catalyst, performing anionic polymerization on 1,2-propylene oxide and adding ethylene oxide for terminating; the polyether polyol 2 is propylene oxide polyether polyol with the functionality being 2, and is prepared by taking bisphenol A as an initiator; the polyether polyol 3 is prepared by taking glycerol as an initiator and is terminated by ethylene oxide; the polyester polyol 1 is obtained by polycondensation reaction between terephthalic acid and ethylene glycol.

An anti-viral compounds effective against viruses belonging to the Flaviviridae family, wherein the anti-viral compounds are 1,5-dideoxy-1,5-imino-D-glucitol derivative compounds having the general formula (I)

wherein R², R³, R⁴ and R⁵ are the same or different and are selected from the group consisting of hydrogen, acyl, benzyl, alkyl, aryl, sulfonyl, phosphonyl, silyl, R6 is at least one of alkyl or branched alkyl, heteroalkyl or aryl, R_6′ is a bridging group selected from at least one of bicycle[2.2.1]heptyl, bicycle[3.2.1]octyl, oxa analogs, admonyl and cubyl, n′=2-10, n″=1-10, enantiomers and stereoisomers of said compounds and physiologically acceptable salts or solvates of said compounds, enantiomer or stereoisomer.

The present invention provides a pharmaceutical composition useful as a therapeutic agent for fatty liver disease. A pharmaceutical composition, which comprises (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, (1S)-1,5-anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, or alternatively, (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, more specifically such a pharmaceutical composition for treating fatty liver disease, such as nonalcoholic fatty liver disease in one embodiment, or nonalcoholic simple fatty liver and/or nonalcoholic steatohepatitis in another embodiment.

The present invention provides a peritoneal dialysis solution that contains heat stable osmotic agents such as D-glucitols, gluconic acids and alkylglycosides produced the reduction, oxidation or glycosylation of icodextrins respectively. As a result, osmotic agents that are stable under autoclaving or heat sterilization conditions are provided which reduces the amount of bioincompatible materials in the sterilized peritoneal dialysis solutions. Methods of preparing the D-glucitols, gluconic acids and alkylglycosides are disclosed.

The invention discloses a high-concentration glucose removal method for determining serum 1,5 anhydro-D-glucitol based on a pyranose oxidase method, which comprises the following steps: preparing a 2-morpholinoethanesulfonic acid (MES) buffer solution having a pH value of 6.0-9.0, wherein the MES buffer solution contains a certain amount of glucokinase (GK), glucose-6-phosphate dehydrogenase (G6PD), nicotinamide adenine dinucleotide phosphate (NADP), pyruvate kinase (PK), phosphoenolpyruvate (PEP) and adenosine triphosphate (ATP); and adding into a serum sample containing glucose (Glu), and reacting at 20-50 DEG C for 3-5 minutes, wherein the GK converts the Glu into glucose-6-phosphoric acid (G6P) in the presence of the ATP, and adenosine diphosphate (ADP) is generated at the same time; the G6P is further converted into glucose-6-phosphate lactone (G6PL) by the G6PD in the presence of the NADP+; and the ADP generated in the reaction is converted into ATP again under the action of thePK in the presence of the PEP. The glucose removal agent prepared by the method can be stably stored at 2-8 DEG C for 14 months, and can be used for a clinical biochemical autoanalyzer extensively used at present.

The invention discloses a pancreatic cancer diagnostic marker combination as well as application and a determination method thereof. The pancreatic cancer diagnostic marker combination comprises 15 differentiated metabolites (2,5-dihydroxybenzoic acid, talopyranose, proline, glutamate, choline, 1,5-anhydro-D-glucitol, tryptophan, glutamine, betaine, 2-oxoglutaric acid, methylguanidine, adenine, glycocholic acid, valine and 2-aminobutyric acid). The invention further provides a combination of the 15 differentiated metabolites to serve as a marker for early discovery and diagnosis of pancreatic cancer, application and a diagnostic marker determination method, and the method is a liquid-phase/gas-phase chromatography-mass spectrometry combined metabonomics analysis method based on plasma/serum of patients with pancreatic cancer. The pancreatic cancer diagnostic marker combination provided by the technical scheme of the invention has the characteristics of being high in sensitiveness and specificity, has relatively high sensitiveness and specificity on early pancreatic cancer diagnosis, can be used for early discovery of pancreatic cancer, gains time for the patients to receive treatment as soon as possible, and improves the clinical treatment effect.

N-Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of Formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula I may be used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents.

A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like:

or a pharmaceutically acceptable salt thereof or a hydrate thereof, or a pharmaceutical preparation comprising the same as an active ingredient is useful as a novel type of prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which inhibits both SGLT1 and SGLT2 activities to achieve not only suppression of glucose absorption from the digestive tract but also excretion of urinary sugars.

The invention discloses an reagent for enzymatic determination of 1,5-anhydro-D-glucitol. At present, determination operation has a lot of trouble and is difficult to be detected in bulk, and in the methods for the operation, the reagent only can be prepared when being used without long term preservation. The reagent of the invention comprises the following components with the contents in 1 liter of water: 60-140 mmol of 3-hydroxyl methyl amino methane, 2.26-2.38 mmol of oxidized coenzyme II (NADP+), 1-5 grams of trehalose, 0.1-0.6 activity unit of 2-methyl-4-isothiazole-3-ketone, 0.1-0.6 gram of Twain, 1000-3000U of ADP-dependent hexokinase (ADP-HK), 1000-80000U of AG-6-phosphate dehydrogenase and 0.1-0.3 mmol of adenosine diphosphate (ADP). The invention is used for determining 1,5- anhydro-D-glucitol.

Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

The present invention relates to methods and compositions of treating or preventing inflammatory diseases or conditions in a patient comprising administering to the patient a therapeutically effective amount of a composition comprising a glutathione donor, 5-amino 4-i mid azolecarboxamide ribotide (AICAR), a 3-hydroxy-3-methylgluatryl-coenzymeA (HMG-CoA) reductase inhibitor, D-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol HCl (D-PDMP), and/or 1,5-(butylimino)-1,5-dideoxy-D-glucitol (Miglustat), or derivatives thereof.

The invention discloses a rose beautifying beef jerk and a preparation method thereof. The rose beautifying beef jerk is prepared from the following raw materials in parts by weight: 1-2 parts of green onion juice, 1-2 parts of rose powder, 2-3 parts of periwinkie meat, 4-5 parts of grape seed oil, 0.5-1 parts of platycodon grandiflorum, 0.5-1 parts of buckwheat, 0.5-1 parts of cushaw flowers, 100-110 parts of beef, 0.4-0.5 parts of papain, 1.8-2.0 parts of calcium chloride, 1.8-2.0 parts of D-Glucitol, 5-6 parts of edible salt, 0.03-0.04 parts of Lactobacillus casei, 0.1-0.2 parts of SodiuM different VC, 12-15 parts of Ginger slice, 10-12 parts of ginger juice, 2-3 parts of aginomoto, 5-6 parts of white granulated sugar, 1-2 parts of soy sauce, 6-8 parts of yellow rice or millet wine, 3-4 parts of pepper, 1-2 parts of cinnamon, 1-2 parts of anise, 1-2 parts of fennel, 18-20 parts of 140mg/ml tangerine peel extracting liquid, and a proper amount of water. The production technology is good, the mouthfeeling is refreshing and smooth, rose can beautify the skin, and the added traditional Chinese medicines have efficacies of relieving cough and eliminating phlegm.

Novel compounds, called liamocins from Aureobasidium pullulans, having the general structure in Formula 1 are disclosed.

where R₁ is either COCH₃ or H; and R₂ is between two to ten O-linked 3,5-dihydroxydecanoate; and R₃ can be a polyol (e.g., L- or D-glycerol, L- or D-threitol, L- or D-erythritol, L- or D-arabitol, L- or D-xylitol, L- or D-lyxitol, L- or D-ribitol, L- or D-allitol, L- or D-altritol, L- or D-mannitol, L- or D-iditol, L- or D-gulitol, L- or D-glucitol (also called sorbitol), L- or D-galactitol (also called dulcitol), and L- or D-talitol), 2-amino-D-mannitol, 2N-acetylamino-D-mannitol, L-rhamnitol, or D-fucitol; except when R₃ is D-mannitol, R₂ is not 2 nor 3 O-linked 3,5-dihydroxydecanoate chains. These liamocins described above in addition to D-mannitol liamocin A1, D-mannitol liamocin A2, D-mannitol liamocin B1, and D-mannitol liamocin B2, alone or in combination with each other, can be used to kill certain bacteria and to treat certain bacterial infections.